Japanese gastroenterology giant Takeda (TYO: 4502) has inked a deal with German firms Zedira and Dr Falk Pharma for the development of a celiac disease candidate, TAK-227.
The investigational therapy is in Phase IIb testing, and represents a potential first-in-class option for people with the autoimmune condition, which has a significant impact on quality of life.
The drug is designed to prevent the immune response to gluten which typifies the disease, a consequence of which is inflammation and damage to the small intestine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze